<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01808846</url>
  </required_header>
  <id_info>
    <org_study_id>1001006251</org_study_id>
    <secondary_id>R01DK085577</secondary_id>
    <nct_id>NCT01808846</nct_id>
  </id_info>
  <brief_title>Neural Functioning of Feeding Centers in Obese Youth</brief_title>
  <official_title>Neural Functioning of Feeding Centers in Obese Youth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore whether obese adolescents with insulin resistance and relative low leptin levels
      exhibit functional alterations of the neuronal circuits involved in the regulation of energy
      metabolism and food seeking behaviors.

      We here propose to test the hypothesis that the reward circuitry is dysregulated in obese
      adolescents and is related to the degree of insulin resistance and hyperinsulinemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Functional Magnetic Resonance Imaging (fMRI) provides a non-invasive method to assess the
      functional pathways affected by nutrient ingestion and therefore can help answer important
      questions regarding potential differences in the response of brain regions involved in
      feeding.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2010</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>measure of cerebral blood flow response to glucose ingestion</measure>
    <time_frame>Baseline and 2 year follow up</time_frame>
    <description>fmri on 3T to measure blood flow response after ingestion of glucose drink</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>measure of cerebral blood flow response to fructose ingestion</measure>
    <time_frame>Baseline and 2 year follow up</time_frame>
    <description>fmri on 3T to measure blood flow response after ingestion of fructose drink</description>
  </secondary_outcome>
  <other_outcome>
    <measure>measure of BOLD signal brain reactivity to food cues</measure>
    <time_frame>Baseline and 2 year follow up</time_frame>
    <description>fmri on 3T to measure blood flow response to visually presented food cues</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">51</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Lean Adolescents</arm_group_label>
    <description>Kids aged 12-17 with body mass index less than 25% and normal glucose tolerance test results</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese Insulin Sensitive</arm_group_label>
    <description>Obese Insulin Sensitive Adolescents aged 12-17 with BMI&gt;95th% and whole body insulin sensitivity index &gt; 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese Insulin Resistant Adolscent</arm_group_label>
    <description>Obese Insulin Resistant Adolescents 12-17 with BMI&gt; 95th% and WBISI&lt;1.2.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Clinic patients of Dr. Caprio at the Yale Pediatric Obesity Clinic who have undergone oral
        glucose tolerance testing (OGTT) and found to be insulin resistant or sensitive and/or
        previous research subjects who were found to be insulin resistant or sensitive and who
        agreed to be contacted for other studies will be contacted.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese adolescents

          -  Good general health,

          -  taking no medication on a chronic basis

          -  Age 12 to 17 yrs,

          -  in puberty (girls and boys: Tanner stage II - IV)

        Obese Insulin Resistant Adolescents

          -  (BMI&gt; 95th)

          -  (WBISI&lt;1.2 plus a low adiponectin &lt;6 ug/dl and

          -  high triglyceride levels &gt;130mg/dl)

        Obese Insulin Sensitive Adolescents

          -  (BMI&gt;95th)

          -  (WBISI &gt;3) plus high adiponectin &gt;8 ug/ml and

          -  triglyceride levels &gt; 80 mg/dl Girls who begin menstruating must have a negative
             pregnancy test during the study

        Eligibility criteria for healthy non-obese children and adolescents:

          -  Brother or sister with obesity

          -  Age 12 to 17 years

          -  Normal fasting glucose and lipids in the child, and

          -  normal OGTT

          -  No use of any medication known to affect glucose, lipid metabolism and inflammation

          -  No endocrinopathies

          -  No use of any antipsychotic medication

          -  BMI &gt;25th to &lt;75th ( Center for Disease Control (CDC) BMI Charts)

          -  Minimum weight of 90lbs (CDC Growth Charts)

        Exclusion Criteria

          -  Baseline creatinine &gt;1.0 mg

          -  Pregnancy

          -  Presence of endocrinopathies (e.g. Cushing syndrome)

          -  Cardiac or pulmonary or other significant chronic illness

          -  Adolescents with psychiatric disorder or with substance abuse determined via
             self-report.

          -  Use of anorexic agents No metal implants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonia Caprio, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2013</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Sonia Caprio</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>functional magnetic resonance imaging</keyword>
  <keyword>glucose</keyword>
  <keyword>fructose</keyword>
  <keyword>hypothalamus</keyword>
  <keyword>neuronal circuits</keyword>
  <keyword>feeding behavior</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

